We are monitoring the impact of COVID-19 on North America Solid Tumor Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 6298
Share on
Share on

North America Solid Tumor Market Research Report – Segmented By Disease, Drugs and Country (the United States, Canada and Rest of North America) - Industry Analysis, Size, Share, Growth, Trends and Forecast (2021 to 2026)

Pulished: April, 2021
ID: 6298
Pages: 145

North America Solid Tumor Market (2021 to 2026)

The Solid Tumor Market in North America is predicted to showcase a healthy CAGR during the forecast period.  North America led with the highest shares of the Global Solid Tumor Market and is estimated to maintain its dominance on the market over the forecast period.

The primary factors driving the North American Solid Tumor Market's growth include increasing solid tumors patients, the rising pervasiveness of various forms of metastatic cancers, an increasing market for highly effective chemotherapeutic agents, and a ripe pipeline of drugs which is available in the global market. Increasing investment in clinical trials and R & D of cancer drugs and increasing healthcare expenditure by the region's population are other vital factors that are expected to fuel the North America Solid Tumor therapeutics market.

Other factors responsible for the North American Solid tumor market's expansion include new product licenses in ovarian, pancreatic, prostate cancers, and increasing government initiatives for cancer awareness.

The high expense of cancer therapy, an increase in drug patent cliff, and the increasing size of nonproprietary therapeutic products are anticipated to be the growth hindering factors for the North America Solid Tumor therapeutics market.

This research report has been segmented and sub-segmented into the following categories:

By Disease:

  • Breast cancer   
  • Lung cancer    
  • Colorectal cancer
  • Prostate cancer
  • Cervical cancer
  • Others   

By Drugs:

  • Carboplatin    
  • Cisplatin  
  • Gemcitabine    
  • Paclitaxel
  • Doxorubicin    
  • Bevacizumab   
  • Erlotinib  
  • Sunitinib  
  • Everolimus    
  • Docetaxel    
  • Abiraterone   
  • Abiraterone acetate   
  • Cabazitaxel

By Country:

  • The United States
  • Canada
  • Rest of North America

Regionally, the Global Solid Tumor market was dominated by North America due to the high incidence rate of various solid tumor cases and the very well-developed healthcare infrastructure of these regions. North America dominated the global Solid Tumor market driven by best in class infrastructure, best in industry practices, and higher expenditure by the citizens towards healthcare expenditure. In North America, the United States holds the largest market share. It can be majorly credited to growing cancer cases. Increasing awareness among people and the presence of developed healthcare infrastructure is propelling the growth of the market in the forecast period.

Some of the major players operating in the North America Solid Tumor Market profiled in this report are Baxter International, Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, AstraZeneca plc, Abbott Laboratories, Inc., Amgen, Inc., Biogen Idec, Inc., Boehringer Ingelheim GmbH, Johnson & Johnson, GlaxoSmithKline plc, Kyowa Hakko Kirin Co., Ltd., and Sanofi among others.

Recent Market Developments in This Region:

  • On January 13, 2020, Amgen made a public statement that it will collaborate with two business lading diagnostic companies Guardant and QIAGEN N.V., to develop the blood- tissue companion diagnostics. The agreement between the companies will focus on treatment procedures for non-small cell lung cancer.
  • On March 11, 2020, the liver cancer drug officially received approval from the FDA, which Bristol-Myers Squibb Company introduced.

1.Introduction                                 

               1.1 Market Definition                    

               1.2 Study Deliverables                   

               1.3 Base Currency, Base Year and Forecast Periods                           

               1.4 General Study Assumptions                  

2. Research Methodology                                          

               2.1 Introduction               

               2.2 Research Phases                      

                              2.2.1 Secondary Research            

                              2.2.2 Primary Research  

                              2.2.3 Econometric Modelling      

                              2.2.4 Expert Validation   

               2.3 Analysis Design                         

               2.4 Study Timeline                          

3. Overview                                     

               3.1 Executive Summary                 

               3.2 Key Inferences                          

               3.3 Epidemology                             

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                        

               4.1 Market Drivers                         

               4.2 Market Restraints                    

               4.3 Key Challenges                         

               4.4 Current Opportunities in the Market                 

5. Market Segmentation                              

               5.1 Disease                       

                              5.1.1 Introduction           

                              5.1.2 Breast cancer         

                              5.1.3 Lung cancer            

                              5.1.4 Colorectal cancer  

                              5.1.5 Prostate cancer     

                              5.1.6 Cervical cancer      

                              5.1.7 Others       

                              5.1.8  Y-o-Y Growth Analysis, By disease 

                              5.1.9  Market Attractiveness Analysis, By disease 

                              5.1.10  Market Share Analysis, By disease

               5.2 Drugs                           

                              5.2.1 Introduction           

                              5.2.2 Carboplatin             

                              5.2.3 Cisplatin   

                              5.2.4 Gemcitabine           

                              5.2.5 Paclitaxel 

                              5.2.6 Doxorubicin            

                              5.2.7 Bevacizumab          

                              5.2.8 Erlotinib    

                              5.2.9 Sunitinib   

                              5.2.10 Everolimus            

                              5.2.11 Docetaxel             

                              5.2.12 Abiraterone          

                              5.2.13 Abiraterone acetate          

                              5.2.14 Cabazitaxel           

                              5.2.15 Y-o-Y Growth Analysis, By Drugs   

                              5.2.16 Market Attractiveness Analysis, By drugs   

                              5.2.17 Market Share Analysis, By drugs    

6. Geographical Analysis                              

               6.1 Introduction               

                              6.1.1 Regional Trends     

                              6.1.2 Impact Analysis      

                              6.1.3 Y-o-Y Growth Analysis         

                                             6.1.3.1 By Geographical Area

                                             6.1.3.2 By disease

                                             6.1.3.3 By drugs

                              6.1.4  Market Attractiveness Analysis       

                                             6.1.4.1 By Geographical Area

                                             6.1.4.2 By disease

                                             6.1.4.3 By drugs

                              6.1.5  Market Share Analysis        

                                             6.1.5.1 By Geographical Area

                                             6.1.5.2 By disease

                                             6.1.5.3 By drugs

               6.2 United States                            

               6.3 Canada                        

7. Strategic Analysis                                      

               7.1 PESTLE analysis                        

                              7.1.1 Political    

                              7.1.2 Economic 

                              7.1.3 Social        

                              7.1.4 Technological        

                              7.1.5 Legal         

                              7.1.6 Environmental       

               7.2 Porter’s Five analysis              

                              7.2.1 Bargaining Power of Suppliers         

                              7.2.2 Bargaining Power of Consumers     

                              7.2.3 Threat of New Entrants      

                              7.2.4 Threat of Substitute Products and Services  

                              7.2.5 Competitive Rivalry within the Industry        

8. Market Leaders' Analysis                                        

               8.1 Abbott Laboratories                

                              8.1.1 Overview  

                              8.1.2 Product Analysis    

                              8.1.3 Financial analysis   

                              8.1.4 Recent Developments         

                              8.1.5 SWOT analysis       

                              8.1.6 Analyst View           

               8.2 Boehringer Ingelheim GmbH                

               8.3 Baxter International                

               8.4 Bristol-Myers Squibb Company                           

               8.5 F. Hoffmann-La Roche Ltd.                  

               8.6 Eli Lilly and Company                             

               8.7 Johnson & Johnson                 

               8.8 GlaxoSmithKline plc                 

               8.9 Kyowa Hakko Kirin Co., Ltd.                 

               8.10 Sanofi                        

9. Competitive Landscape                                          

               9.1 Market share analysis                            

               9.2 Merger and Acquisition Analysis                         

               9.3 Agreements, collaborations and Joint Ventures                           

               9.4 New Product Launches                          

10. Market Outlook and Investment Opportunities                                           

Appendix                                          

               a) List of Tables                

               b) List of Figures              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms Disease and Drug along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. North America Solid Tumor Market, By Disease, From 2021 to 2026 (USD Million)
  2. North America Breast cancer Market, By Region, From 2021 to 2026 (USD Million)
  3. North America Lung cancer Market, By Region, From 2021 to 2026 (USD Million)
  4. North America Liver cancer Market, By Region, From 2021 to 2026 (USD Million)
  5. North America Colorectal cancer Market, By Region, From 2021 to 2026 (USD Million)
  6. North America Cervical cancer Market, By Region, From 2021 to 2026 (USD Million)
  7. North America Prostate cancer Market, By Region, From 2021 to 2026 (USD Million)
  8. North America Others Market, By Region, From 2021 to 2026 (USD Million)
  9. North America Solid Tumor Market, By Drugs, From 2021 to 2026 (USD Million)
  10. North America Carboplatin Market, By Region, From 2021 to 2026 (USD Million)
  11. North America Cisplatin Market, By Region, From 2021 to 2026 (USD Million)
  12. North America Doxorubicin Market, By Region, From 2021 to 2026 (USD Million)
  13. North America Paclitaxel Market, By Region, From 2021 to 2026 (USD Million)
  14. North America Erlotinib Market, By Region, From 2021 to 2026 (USD Million)
  15. North America Suntinib Market, By Region, From 2021 to 2026 (USD Million)
  16. North America Everolimus Market, By Region, From 2021 to 2026 (USD Million)
  17. North America Docetaxel Market, By Region, From 2021 to 2026 (USD Million)
  18. North America Abiraterone acetate Market, By Region, From 2021 to 2026 (USD Million)
  19. North America Others Market, By Region, From 2021 to 2026 (USD Million)
  20. United States Solid Tumor Market, By Disease, From 2021 to 2026 (USD Million)
  21. United States Solid Tumor Market, By Drugs, From 2021 to 2026 (USD Million)
  22. Canada Solid Tumor Market, By Disease, From 2021 to 2026 (USD Million)
  23. Canada Solid Tumor Market, By Drugs, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample